Enhancing the Efficacy of Hormonal Agents With Selected Targeted Agents

2009 ◽  
Vol 3 (1) ◽  
pp. 30-38
Author(s):  
Stephen R. D. Johnston
Keyword(s):  
Targeted Agents

Activation of human immune cells by the oncolytic parvovirus H-1 combined with chemotherapeutic or targeted agents

2010 ◽  
Vol 48 (08) ◽  
Author(s):  
M Moehler ◽  
M Sieben ◽  
S Roth ◽  
B Leuchs ◽  
C Dinsart ◽  
...  
Keyword(s):  
Immune Cells ◽  
Targeted Agents ◽  
Human Immune

Targeted Agents for the Treatment of Advanced Renal Cell Carcinoma

2005 ◽  
Vol 6 (7) ◽  
pp. 835-846 ◽  
Author(s):  
M. Staehler ◽  
K. Rohrmann ◽  
N. Haseke ◽  
C. Stief ◽  
M. Siebels
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Targeted Agents

scholarly journals Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer

2021 ◽  
Vol 22 (5) ◽  
pp. 2625
Author(s):  
Sara Elena Rebuzzi ◽  
Lodovica Zullo ◽  
Giovanni Rossi ◽  
Massimiliano Grassi ◽  
Veronica Murianni ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Molecular Targets ◽  
Small Cell ◽  
Targeted Agents ◽  
Small Cell Lung ◽  
Epidermal Growth

In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one of the most relevant breakthroughs is represented by targeted therapies. Throughout the last years, inhibitors of the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-Ros oncogene 1 (ROS1), and V-raf murine sarcoma viral oncogene homolog B (BRAF) have been approved and are currently used in clinical practice. However, other promising molecular drivers are rapidly emerging as therapeutic targets. This review aims to cover the molecular alterations with a potential clinical impact in NSCLC, including amplifications or mutations of the mesenchymal–epithelial transition factor (MET), fusions of rearranged during transfection (RET), rearrangements of the neurotrophic tyrosine kinase (NTRK) genes, mutations of the Kirsten rat sarcoma viral oncogene (KRAS) and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA), as well as amplifications or mutations of human epidermal growth factor receptor 2 (HER2). Additionally, we summarized the current status of targeted agents under investigation for such alterations. This revision of the current literature on emerging molecular targets is needed as the evolving knowledge on novel actionable oncogenic drivers and targeted agents is expected to increase the proportion of patients who will benefit from tailored therapeutic approaches.

scholarly journals Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases

2021 ◽  
Vol 14 (3) ◽  
pp. 251 ◽  
Author(s):  
Eun Ha Kang ◽  
Yeong Wook Song
Keyword(s):  
Rheumatic Diseases ◽  
Treatment Options ◽  
Treatment Strategies ◽  
Pulmonary Involvement ◽  
Current Treatment ◽  
Targeted Agents ◽  
Pharmacological Interventions ◽  
Inflammatory Processes ◽  
Pulmonary Arterial ◽  
Epidemiologic Features

Among the diverse forms of lung involvement, interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are two important conditions in patients with rheumatic diseases that are associated with significant morbidity and mortality. The management of ILD and PAH is challenging because the current treatment often provides only limited patient survival benefits. Such challenges derive from their common pathogenic mechanisms, where not only the inflammatory processes of immune cells but also the fibrotic and proliferative processes of nonimmune cells play critical roles in disease progression, making immunosuppressive therapy less effective. Recently, updated treatment strategies adopting targeted agents have been introduced with promising results in clinical trials for ILD ad PAH. This review discusses the epidemiologic features of ILD and PAH among patients with rheumatic diseases (rheumatoid arthritis, myositis, and systemic sclerosis) and the state-of-the-art treatment options, focusing on targeted agents including biologics, antifibrotic agents, and vasodilatory drugs.

scholarly journals Molecularly profiled trials: toward a framework of actions for the “nil actionables”

2021 ◽  
Author(s):  
Allan Michael Jordan
Keyword(s):  
Holistic Approach ◽  
Step Change ◽  
Additional Patient ◽  
Targeted Agents ◽  
Patient Benefit ◽  
Blood Samples ◽  
Left Behind ◽  
Clinical Community ◽  
Molecularly Targeted Agents ◽  
Early Drug

AbstractThe sequencing of tumour or blood samples is increasingly used to stratify patients into clinical trials of molecularly targeted agents, and this approach has frequently demonstrated clinical benefit for those who are deemed eligible. But what of those who have no clear and evident molecular driver? What of those deemed to have “nil actionable” mutations? How might we deliver better therapeutic opportunities for those left behind in the clamour toward stratified therapeutics? And what significant learnings lie hidden in the data we amass but do not interrogate and understand? This Perspective article suggests a holistic approach to the future treatment of such patients, and sets a framework through which significant additional patient benefit might be achieved. In order to deliver upon this framework, it encourages and invites the clinical community to engage more enthusiastically and share learnings with colleagues in the early drug discovery community, in order to deliver a step change in patient care.

Epidermal Growth Factor Receptor-Targeted Agents for Lung Cancer

2006 ◽  
Vol 13 (2) ◽  
pp. 129-140 ◽  
Author(s):  
Petra Martin ◽  
Catherine M. A. Kelly ◽  
Desmond Carney
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Targeted Agents ◽  
Epidermal Growth

scholarly journals Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer

2011 ◽  
Vol 11 (2) ◽  
pp. 439-451 ◽  
Author(s):  
Hyun-Jin Nam ◽  
Keith A. Ching ◽  
Julie Kan ◽  
Hwang-Phill Kim ◽  
Sae-Won Han ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Targeted Agents ◽  
Antitumor Effects

scholarly journals Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma

2013 ◽  
Vol 2 (5) ◽  
pp. e24320 ◽  
Author(s):  
Zachary A. Cooper ◽  
Dennie T. Frederick ◽  
Zain Ahmed ◽  
Jennifer A. Wargo
Keyword(s):  
Metastatic Melanoma ◽  
Checkpoint Inhibitors ◽  
Targeted Agents
Sign in / Sign up

Export Citation Format

Share Document